You bring the thesis, we bring the deal flow.

Torrent paid 24.8x EBITDA for JB Chemicals. Most pharma promoters in India will never understand why. That gap is the whole opportunity.

KKR bought JB Chemicals in 2020 for roughly Rs. 3,100 Cr. Torrent paid Rs. 25,689 Cr in 2025. The business did not change sectors. The asset class did not rerate. What changed is what KKR built inside the business, and it is exactly what most founder-owned pharma businesses are missing.